NGM Biopharmaceuticals, Inc.
Compositions and Methods for Treatment of Metabolic Disorders and Diseases

Last updated:

Abstract:

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

Status:
Application
Type:

Utility

Filling date:

10 Aug 2020

Issue date:

10 Jun 2021